INTERIM REPORT 1 APRIL– 30 JUNE 2018
“Our business in Europe is growing, driven by Germany which now starts to show signs of real commercial progress. In parallel, we have developed a robust clinical strategy targeting a US FDA approval and have taken a significant step in US by the filing of our IDE application”, says Pål Ryfors, CEO Episurf Medical.Second quarter 2018 compared to 2017, Group » Gross order intake increased by 104% and amounted to SEK 1.1m (0.6) » Order backlog amounted to SEK 1.1m (0.5) » 54% growth in orders for Episealer® knee implants during the quarter with 43 (28) approved orders » Group net